Impact of human serum albumin on oritavancin in vitro activity against enterococci.
Oritavancin is a lipoglycopeptide with activity against gram-positive pathogens including vancomycin-resistant enterococci. The impact of human serum albumin (HSA) on oritavancin activity against enterococci was compared to those of vancomycin, daptomycin, teicoplanin, and linezolid in vitro using MIC and time-kill methods. Oritavancin MICs increased between 0- and 8-fold in the presence of HSA. In time-kill assays with HSA, oritavancin retained activity, killing or inhibiting enterococci more rapidly than did comparators when peak concentrations were simulated.
McKay
Geoffrey A
GA
Targanta Therapeutics Incorporated, 7170 Frederick Banting, St. Laurent, Quebec, Canada H4S 2A1.
Beaulieu
Sylvain
S
Sarmiento
Ingrid
I
Arhin
Francis F
FF
Parr
Thomas R
TR
Moeck
Gregory
G
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D016983:Enterococcus / Q000187:drug effects*; D006020:Glycopeptides / Q000378:metabolism / Q000494:pharmacology*; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism*; D014640:Vancomycin / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D012709:Serum Albumin; C100708:oritavancin; D014640:Vancomycin